HK Stock Movement | CSTONE PHARMA-B (02616) Rises Over 5% as EU Approves Sugemalimab for Stage III NSCLC Treatment

Stock News11-27

CSTONE PHARMA-B (02616) surged nearly 7% intraday, and as of press time, it was up 5.22% at HK$6.25, with a turnover of HK$39.03 million.

The catalyst behind the rally is the announcement that the European Commission (EC) has approved a new indication for sugemalimab: as a monotherapy for adult patients with unresectable Stage III non-small cell lung cancer (NSCLC) whose tumor cells express PD-L1 ≥1%, lack EGFR-sensitive mutations or ALK/ROS1 genomic alterations, and have not progressed after platinum-based chemoradiotherapy (CRT).

Dr. Yang Jianxin, CEO, R&D President, and Executive Director of CSTONE PHARMA-B, stated, "Following the EC's initial approval of sugemalimab for first-line treatment of metastatic squamous and non-squamous NSCLC in 2024, this new indication approval comes just one year later. This marks sugemalimab's full coverage from Stage III to IV NSCLC in Europe, offering a new treatment option for a broader patient population. CSTONE PHARMA-B remains committed to enhancing global accessibility to sugemalimab, fulfilling our long-term promise to patients."

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1183957986?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-27 13:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1183957986","market":"sh","top_or_hot":-1,"title":"HK Stock Movement | CSTONE PHARMA-B (02616) Rises Over 5% as EU Approves Sugemalimab for Stage III NSCLC Treatment","media":"Stock News","content":"<p>CSTONE PHARMA-B (02616) surged nearly 7% intraday, and as of press time, it was up 5.22% at HK$6.25, with a turnover of HK$39.03 million.</p>\n<p>The catalyst behind the rally is the announcement that the European Commission (EC) has approved a new indication for sugemalimab: as a monotherapy for adult patients with unresectable Stage III non-small cell lung cancer (NSCLC) whose tumor cells express PD-L1 ≥1%, lack EGFR-sensitive mutations or ALK/ROS1 genomic alterations, and have not progressed after platinum-based chemoradiotherapy (CRT).</p>\n<p>Dr. Yang Jianxin, CEO, R&D President, and Executive Director of CSTONE PHARMA-B, stated, \"Following the EC's initial approval of sugemalimab for first-line treatment of metastatic squamous and non-squamous NSCLC in 2024, this new indication approval comes just one year later. This marks sugemalimab's full coverage from Stage III to IV NSCLC in Europe, offering a new treatment option for a broader patient population. CSTONE PHARMA-B remains committed to enhancing global accessibility to sugemalimab, fulfilling our long-term promise to patients.\"</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HK Stock Movement | CSTONE PHARMA-B (02616) Rises Over 5% as EU Approves Sugemalimab for Stage III NSCLC Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHK Stock Movement | CSTONE PHARMA-B (02616) Rises Over 5% as EU Approves Sugemalimab for Stage III NSCLC Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-11-27 13:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CSTONE PHARMA-B (02616) surged nearly 7% intraday, and as of press time, it was up 5.22% at HK$6.25, with a turnover of HK$39.03 million.</p>\n<p>The catalyst behind the rally is the announcement that the European Commission (EC) has approved a new indication for sugemalimab: as a monotherapy for adult patients with unresectable Stage III non-small cell lung cancer (NSCLC) whose tumor cells express PD-L1 ≥1%, lack EGFR-sensitive mutations or ALK/ROS1 genomic alterations, and have not progressed after platinum-based chemoradiotherapy (CRT).</p>\n<p>Dr. Yang Jianxin, CEO, R&D President, and Executive Director of CSTONE PHARMA-B, stated, \"Following the EC's initial approval of sugemalimab for first-line treatment of metastatic squamous and non-squamous NSCLC in 2024, this new indication approval comes just one year later. This marks sugemalimab's full coverage from Stage III to IV NSCLC in Europe, offering a new treatment option for a broader patient population. CSTONE PHARMA-B remains committed to enhancing global accessibility to sugemalimab, fulfilling our long-term promise to patients.\"</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1574","symbol_name":"生物医药B类股","start_time":0,"source_url":"","article_id":"1183957986","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1183957986","pubTimestamp":1764222376,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CSTONE PHARMA-B (02616) surged nearly 7% intraday, and as of press time, it was up 5.22% at HK$6.25, with a turnover of HK$39.03 million. The catalyst behind the rally is the announcement that the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1574":"生物医药B类股","III":"信息服务","BK4134":"信息科技咨询与其它服务","BK1161":"生物科技","02616":"基石药业-B"},"translate_title":"港股动向|基石药业-B(02616)涨超5%因欧盟批准舒格利单抗用于III期非小细胞肺癌治疗","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"III":1,"02616":1},"content_text":"CSTONE PHARMA-B (02616) surged nearly 7% intraday, and as of press time, it was up 5.22% at HK$6.25, with a turnover of HK$39.03 million.\nThe catalyst behind the rally is the announcement that the European Commission (EC) has approved a new indication for sugemalimab: as a monotherapy for adult patients with unresectable Stage III non-small cell lung cancer (NSCLC) whose tumor cells express PD-L1 ≥1%, lack EGFR-sensitive mutations or ALK/ROS1 genomic alterations, and have not progressed after platinum-based chemoradiotherapy (CRT).\nDr. Yang Jianxin, CEO, R&D President, and Executive Director of CSTONE PHARMA-B, stated, \"Following the EC's initial approval of sugemalimab for first-line treatment of metastatic squamous and non-squamous NSCLC in 2024, this new indication approval comes just one year later. This marks sugemalimab's full coverage from Stage III to IV NSCLC in Europe, offering a new treatment option for a broader patient population. CSTONE PHARMA-B remains committed to enhancing global accessibility to sugemalimab, fulfilling our long-term promise to patients.\"","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1183957986","isCrawlerRequest":true}